Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases World-class leaders in the thymus, immunology, oncology, cell therapy, and drug development will inform and support the Company’s efforts to preserve, restore, and manipulate the thymus to address…
Read More
Tolerance Bio, Inc. Launches With $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases Led by industry innovator Francisco Leon, M.D., Ph.D., Tolerance Bio is developing thymus preservation, regeneration, and manipulation platforms to prevent and treat immune diseases Financing led by Columbus Venture Partners, with participation by…
Read More